ReviewArchives of dermatological research2025
Efficacy of topical sildenafil formulations in enhancing wound healing outcomes: a narrative review.
Review in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Repurposing PDE5-Inhibitors: Sildenafil Drives Arteriogenesis via Localized Regenerative Inflammation.International journal of molecular sciences · 2026Article
- Off-Label Sildenafil Citrate as a Rescue Therapy for Areolar Venous Congestion Post-Breast Reduction: Case Series and Outcomes.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sildenafil, a major phosphodiesterase type 5 (PDE5) inhibitor, is particularly known for treating erectile dysfunction. It has been suggested as a promising therapeutic medication for accelerating wound healing. This study aimed to summarize the efficacy of different formulations and dosages of sildenafil in enhancing wound healing, focusing on its formulations, dosages, and mechanisms of action. The study used relevant keywords to review studies involving animal models and human patients. No time limitation was considered in the current study. The outcomes measured included re-epithelization, vascularization, collagen formation, and overall healing efficacy. Topical sildenafil formulations indicated significant improvements in wound closure, vascularization, and collagen regeneration in skin wounds. A combination of platelet-rich plasma (PRP) and sildenafil increased skin wound healing. Different concentrations (topical 2% and 5% formulation, and 13 mg/kg orally) were useful, with specific dosages showing significant improvements in healing biomarkers. The underlying mechanisms of sildenafil for accelerating wound healing are increasing nitric oxide (NO) levels and collagen synthesis. Moreover, sildenafil triggers angiogenesis, and fibroblast migration and contributes to skin tissue repair and regeneration. Topical sildenafil can be a promising drug for increasing wound healing, with different formulations and dosages illustrating efficacy in improving healing outcomes. Since sildenafil is a cost-efficient, and readily available drug with few side effects, we suggest further research to optimize its use in clinical settings.
Indexed as
Identifiers
40148506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.